Page 1 |
Save page Remove page | Previous | 1 of 23 | Next |
|
small (250x250 max)
medium (500x500 max)
large ( > 500x500)
Full Resolution
All (PDF)
|
This page
All
Subset |
THE
EFFECT
OF
OMALIZUMAB
ON
FREE
IGE
AND
SPIROMETRIC
MEASUREMENTS
IN
ALLERGIC
ASTHMATICS
WITH
HIGHLY
ELEVATED
IGE
LEVELS
by
Sheila
M.
Bonilla
_________________________________________________________________________________________________
A
Thesis
Presented
to
the
FACULTY
OF
THE
USC
GRADUATE
SCHOOL
UNIVERSITY
OF
SOUTHERN
CALIFORNIA
In
Partial
Fulfillment
of
the
Requirements
for
the
Degree
MASTER
OF
SCIENCE
(CLINICAL
AND
BIOMEDICAL
INVESTIGATIONS)
May
2011
Copyright
2011
Sheila
M.
Bonilla
Object Description
| Title | The effect of Omalizumab on free IgE and spirometric measurements in allergic asthmatics with highly elevated IgE levels |
| Author | Bonilla, Sheila M. |
| Author email | sbonilla@usc.edu; sheilabonilla@gmail.com |
| Degree | Master of Science |
| Document type | Thesis |
| Degree program | Clinical & Biomedical Investigations |
| School | Keck School of Medicine |
| Date defended/completed | 2011-04-11 |
| Date submitted | 2011 |
| Restricted until | Unrestricted |
| Date published | 2011-04-14 |
| Advisor (committee chair) |
Allayee, Hooman Barbers, Richard |
| Advisor (committee member) | Azen, Stanley |
| Abstract | INTRODUCTION: Omalizumab has been shown to be well tolerated and effective in the treatment of allergic asthma but the indication is limited to total IgE levels of up to 700 kIU/L. The use of omalizumab in a subgroup of allergic asthmatics with highly elevated IgE has not been reported. OBJECTIVE: To determine whether omalizumab is effective in reducing free IgE levels in patients with total IgE levels of over 700 kIU/L and if this reduction correlates with clinical improvement as measured by spirometry. METHODS: A pilot study of 8 patients with moderate to severe asthma and an elevated IgE levels >1000 kIU/L (+/- 100). Omalizumab was given subcutaneously at a monthly dosage of 0.016mg/kg x total IgE level divided into biweekly, to a maximum of 375 mg per dose. Follow-up was done every six months. Six of 8 patients completed 6 months with free IgE level, spirometry, and asthma classification. Another 2 patients were followed over 2 years. Exhaled nitric oxide (eNO) was measured in one patient for one year. RESULTS: Total IgE levels did not decrease after 6 months on omalizumab treatment but did show a decreasing trend after one year. A similar trend was seen in the free IgE with continued decrease after 2 years in 2 patients. Spirometric values were not affected despite clinical improvement based on decrease in systemic steroid use and decreasing eNO in one patient. CONCLUSIONS: Moderate to severe asthma patients with high serum IgE levels of over >1000 kIU/L showed clinical improvement with omalizumab treatment at the current FDA approved dose that directly correlates with reduced free IgE levels after over one year of treatment. |
| Keyword | asthma; omalizumab; IgE; ABPA; aspergillosis |
| Language | English |
| Part of collection | University of Southern California dissertations and theses |
| Publisher (of the original version) | University of Southern California |
| Place of publication (of the original version) | Los Angeles, California |
| Publisher (of the digital version) | University of Southern California. Libraries |
| Provenance | Electronically uploaded by the author |
| Type | texts |
| Legacy record ID | usctheses-m3747 |
| Rights | Bonilla, Sheila M. |
| Repository name | Libraries, University of Southern California |
| Repository address | Los Angeles, California |
| Repository email | http://www.usc.edu/isd/libraries/services/ask_a_librarian/email/ |
| Filename | etd-Bonilla-4491 |
| Archival file | uscthesesreloadpub_Volume32/etd-Bonilla-4491.pdf |
Description
| Title | Page 1 |
| Full text | THE EFFECT OF OMALIZUMAB ON FREE IGE AND SPIROMETRIC MEASUREMENTS IN ALLERGIC ASTHMATICS WITH HIGHLY ELEVATED IGE LEVELS by Sheila M. Bonilla _________________________________________________________________________________________________ A Thesis Presented to the FACULTY OF THE USC GRADUATE SCHOOL UNIVERSITY OF SOUTHERN CALIFORNIA In Partial Fulfillment of the Requirements for the Degree MASTER OF SCIENCE (CLINICAL AND BIOMEDICAL INVESTIGATIONS) May 2011 Copyright 2011 Sheila M. Bonilla |
Comments
Post a Comment for Page 1
